CJC-1295 with DAC

Description

CJC-1295 with DAC (Growth Hormone Releasing Hormone Analog / Long-Acting GH Secretagogue)

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂
Molecular Weight: 3,364.70 g/mol
Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH₂ (modified with Drug Affinity Complex [DAC])
CAS Number: 863288-34-0
Purity: ≥98% (HPLC)
Form: Lyophilized Powder
Storage: Store at −20°C. Protect from light and moisture.

Description

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH 1–29) engineered for extended half-life and sustained activity.
The inclusion of a DAC moiety allows for covalent binding to serum albumin, dramatically increasing plasma stability and duration of action — extending growth hormone (GH) release for up to 6–8 days per administration in preclinical models.

CJC-1295 with DAC acts as a pituitary GHRH receptor agonist, promoting physiological pulsatile GH secretion while maintaining feedback sensitivity.
It supports research into endocrine modulation, metabolic enhancement, and tissue regeneration, offering a prolonged GH/IGF-1 elevation profile compared to native GHRH or Sermorelin.

This peptide is frequently utilized in combination with GHRPs (e.g., Ipamorelin, GHRP-2, or GHRP-6) to study synergistic GH release and somatotropic axis regulation.

Intended Use

This product is intended for laboratory research use only.
It is not for human consumption, diagnostic, or therapeutic applications.
All handling should be performed by qualified professionals in a controlled research environment.

Key Research Applications

• Investigation of GHRH receptor activation and long-term GH release mechanisms

• Studies on endocrine regulation and IGF-1 axis modulation

• Research on peptide half-life extension via Drug Affinity Complex binding

• Analysis of metabolic, regenerative, and anabolic GH pathways